Melola Discovery

← Melola Discovery

Jurnal SINTA 1

Inhibition of Human Epidermal Growth Factor Receptor-2 (HER-2) from Pomelo (Citrus maxima) Flavonoid Compounds: an In Silico Approach

Indonesian Journal of Cancer Chemoprevention · Vol. 12 No. 3 (2021) · hlm. 148–160

DOI
10.14499/indonesianjcanchemoprev12iss3pp148-160
ISSN
2355-8989, 2088-0197
Terbit
2021-10-31
Penerbit
Indonesian Society for Cancer Chemoprevention
Bahasa
eng

Abstrak

Citrus maxima or pomelo is a plant that has potential as an anticancer because it contains flavonoids. One of the targets of breast anticancer receptors is the HER-2 protein. This research aims to determine the anticancer activity, the toxicity of the compound, and the prediction of physicochemical properties of flavonoids contained in Citrus maxima through in silico approach. Flavonoid compounds were screened using SwissADME with Lipinski's rule of five, Torsion, TPSA, and P-Gp Non-Substrate. Compounds that passed the screening were carried out molecular docking to the HER-2 receptor (PDB ID: 3PP0) using the Molegro Virtual Docker (MVD). The HER-2 receptor (GDP ID: 3PP0) was declared valid because it had RMSD<2Å. The results showed that there were 11 flavonoid compounds that passed the screening and had a lower rerank score than the comparison compound Trastuzumab. Toxicity was predicted using the Protox II online tool and the results showed that the flavonoid compounds were in the safe limits, namely classes 5 and 3. Based on this research, it can be concluded that acacetin, diosmetin, honyucitrin, isosinensetin, nobiletin, sinensetin, and tangeretin can be candidates for breast cancer drugs based on natural ingredients.Keywords: breast cancer, Citrus maxima, HER-2, in silico.

Jaringan kolaborasi para penulis

30 penulis · 85 tautan kepenulisan bersama · 19 lintas organisasi

Arahkan kursor atau ketuk sebuah nama untuk menyorot rekan penulisnya. Klik dua kali untuk membuka halaman penulis.

  • Universitas Islam Negeri Maulana Malik Ibrahim
  • State University of Malang
  • Universitas Trisakti
  • University of Brawijaya
  • Afiliasi tidak diketahui
  • Organisasi berbeda
  • Organisasi sama
  • Afiliasi tidak diketahui
  • Garis lebih tebal = lebih banyak artikel bersama · lingkaran lebih besar = lebih banyak artikel
Tampilkan sebagai tabel
Rekan penulisOrganisasiArtikel bersama
Yen Yen Ari IndrawijayaState University of Malang6
Rahmi AnnisaUniversitas Islam Negeri Maulana Malik Ibrahim3
Alif Firman FirdausyUniversitas Islam Negeri Maulana Malik Ibrahim2
Ana RahmawatiAfiliasi tidak diketahui2
Jauza UlfahAfiliasi tidak diketahui2
Muhammad Firman AmrullohAfiliasi tidak diketahui2
Ferry SandraUniversitas Trisakti1
Farenza Okta KiranaUniversitas Islam Negeri Maulana Malik Ibrahim1
Ana RahmawatiUniversitas Islam Negeri Maulana Malik Ibrahim1
Roihatul Muti'ahAfiliasi tidak diketahui1
Eka Kartini RahmawatiUniversitas Islam Negeri Maulana Malik Ibrahim1
Nurlaili SusantiUniversitas Islam Negeri Maulana Malik Ibrahim1
Muhammad Ragib MustofaUniversitas Islam Negeri Maulana Malik Ibrahim1
Abdul Aziz HakimUniversitas Islam Negeri Maulana Malik Ibrahim1
Ach. NashichuddinUniversitas Islam Negeri Maulana Malik Ibrahim1
Muhammad ZainuddinUniversitas Islam Negeri Maulana Malik Ibrahim1
Trian Sidha MinggarwatiUniversitas Islam Negeri Maulana Malik Ibrahim1
Risma Aprinda KristantiUniversitas Islam Negeri Maulana Malik Ibrahim1
Erna SusantiAfiliasi tidak diketahui1
Syayida Roisatus ZahiroUniversity of Brawijaya1
Hibbatullah HibbbatullahUniversitas Islam Negeri Maulana Malik Ibrahim1
Muhammad Fawaz HarizAfiliasi tidak diketahui1
Burhan Ma’arifState University of Malang1
Ermin RachmawatiState University of Malang1
Ahmad Ulfi BaihaqiAfiliasi tidak diketahui1
Dwi PuspitaState University of Malang1

Afiliasi berasal dari OpenAlex; metadata OAI-PMH jurnal tidak memuatnya. Penulis tanpa ID OpenAlex dicocokkan berdasarkan nama, sehingga dua orang bisa tergabung atau satu orang bisa terpisah.

Sumber metadata: OAI-PMH (metadata jurnal) https://ijcc.chemoprev.org/index.php/ijcc/oai, pertama di-harvest 8 Nov 2026, terakhir terlihat 8 Nov 2026.
Metadata asli (oai_dc)
<oai_dc:dc xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/  http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en-US">Inhibition of Human Epidermal Growth Factor Receptor-2 (HER-2) from Pomelo (Citrus maxima) Flavonoid Compounds: an In Silico Approach</dc:title>
	<dc:creator>Mutiah, Roihatul</dc:creator>
	<dc:creator>Dewi, Tanaya Jati Dharma</dc:creator>
	<dc:creator>Suryadinata, Arief</dc:creator>
	<dc:creator>Qonita, Kesimira</dc:creator>
	<dc:description xml:lang="en-US">Citrus maxima or pomelo is a plant that has potential as an anticancer because it contains flavonoids. One of the targets of breast anticancer receptors is the HER-2 protein. This research aims to determine the anticancer activity, the toxicity of the compound, and the prediction of physicochemical properties of flavonoids contained in Citrus maxima through in silico approach. Flavonoid compounds were screened using SwissADME with Lipinski's rule of five, Torsion, TPSA, and P-Gp Non-Substrate. Compounds that passed the screening were carried out molecular docking to the HER-2 receptor (PDB ID: 3PP0) using the Molegro Virtual Docker (MVD). The HER-2 receptor (GDP ID: 3PP0) was declared valid because it had RMSD&lt;2Å. The results showed that there were 11 flavonoid compounds that passed the screening and had a lower rerank score than the comparison compound Trastuzumab. Toxicity was predicted using the Protox II online tool and the results showed that the flavonoid compounds were in the safe limits, namely classes 5 and 3. Based on this research, it can be concluded that acacetin, diosmetin, honyucitrin, isosinensetin, nobiletin, sinensetin, and tangeretin can be candidates for breast cancer drugs based on natural ingredients.Keywords: breast cancer, Citrus maxima, HER-2, in silico.</dc:description>
	<dc:publisher xml:lang="en-US">Indonesian Society for Cancer Chemoprevention</dc:publisher>
	<dc:contributor xml:lang="en-US">Departement of Pharmacy, Universitas Islam Negeri Maulana Malik Ibrahim Malang</dc:contributor>
	<dc:date>2021-10-31</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:type xml:lang="en-US"></dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://ijcc.chemoprev.org/index.php/ijcc/article/view/393</dc:identifier>
	<dc:identifier>10.14499/indonesianjcanchemoprev12iss3pp148-160</dc:identifier>
	<dc:source xml:lang="en-US">Indonesian Journal of Cancer Chemoprevention; Vol 12, No 3 (2021); 148-160</dc:source>
	<dc:source>2355-8989</dc:source>
	<dc:source>2088-0197</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://ijcc.chemoprev.org/index.php/ijcc/article/view/393/245</dc:relation>
	<dc:relation>https://ijcc.chemoprev.org/index.php/ijcc/article/downloadSuppFile/393/23</dc:relation>
	<dc:relation>https://ijcc.chemoprev.org/index.php/ijcc/article/downloadSuppFile/393/24</dc:relation>
	<dc:relation>https://ijcc.chemoprev.org/index.php/ijcc/article/downloadSuppFile/393/25</dc:relation>
	<dc:relation>https://ijcc.chemoprev.org/index.php/ijcc/article/downloadSuppFile/393/26</dc:relation>
	<dc:relation>https://ijcc.chemoprev.org/index.php/ijcc/article/downloadSuppFile/393/27</dc:relation>
	<dc:rights xml:lang="en-US">Copyright (c) 2022 Indonesian Journal of Cancer Chemoprevention</dc:rights>
</oai_dc:dc>